

Patient safety card

Important safety information for patients taking iptacopan

This material has been developed and funded by Novartis Pharmaceuticals UK Ltd and is intended only for UK patients with complement 3 glomerulopathy (C3G) who have been prescribed iptacopan.

▼ There is additional monitoring in place for iptacopan to help quickly identify new side effects. If you experience any side effects, talk to your doctor, nurse or pharmacist/other healthcare professional. This includes any possible side effects not listed in the leaflet you will find in the package.

Please report suspected side effects to the MHRA through the Yellow Card scheme. You can report via:

- the Yellow Card website www.mhra.gov.uk/yellowcard
- the free Yellow Card app available from the Apple App Store or Google Play Store

Alternatively you can report a suspected side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm. You can leave a message outside of these hours.

When reporting please provide as much information as possible. By reporting side effects, you can help provide more information on the safety of this medicine. If you get side-effects with any medication you are taking, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the information leaflet that comes in the pack.

This material does not replace the package leaflet that comes with your medicine. You should read the package leaflet carefully before you start taking this medicine because it contains important information for you.

During treatment, your immune system has a lower ability to fight certain bacterial infections (specifically from encapsulated bacteria).

These infections may cause meningitis, pneumonia, sepsis or other life-threatening infections. They can cause death if not recognised and treated early.

Keep this card with you at all times during treatment, and for 2 weeks after your last dose in case of an emergency, and show it to any healthcare professional involved in your care.

Contact your doctor immediately or call 999, and show this card, in case you experience any of the following signs and symptoms of serious infection:

• Fever

- With or without shivers or chills
- With a headache
- With a rash
- With chest pain and cough
- With breathlessness/ fast breathing
- With high heart rate

• Headache

- With feeling sick (nausea) or vomiting
- With a stiff neck or stiff back

• Confusion

• Body aches with flu-like symptoms

• Clammy skin

• Eyes sensitive to light

Information for healthcare professionals

This patient is being treated with iptacopan for complement 3 glomerulopathy (C3G).

Iptacopan may increase the patient's susceptibility to serious infections caused by encapsulated bacteria (*Neisseria meningitidis*, *Streptococcus pneumoniae* and *Haemophilus influenzae* type B). These infections include meningitis, pneumonia and sepsis. Serious infections may rapidly progress and may become life-threatening if not recognised and treated early.



Recognise

Immediately evaluate if bacterial infection is suspected.



Treat

Immediate use of antibiotics is vital in cases of suspected meningitis, pneumonia or sepsis.



Inform

Please call the patient's prescribing doctor as soon as possible using the number provided on the last page of this card to receive further information.

Please also note that any adverse events discussed in the course of your consultation should be reported. Please report suspected side effects to the MHRA through the Yellow Card scheme. You can report via:

- the Yellow Card website www.mhra.gov.uk/yellowcard
- the free Yellow Card app available from the Apple App Store or Google Play Store

Alternatively you can report a suspected side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm. You can leave a message outside of these hours.

When reporting please provide as much information as possible. By reporting side effects, you can help provide more information on the safety of this medicine.

In the event of an emergency, please contact 999.

For more information, please refer to the Summary of Product Characteristics for iptacopan.

FA-11414765-1 | Date of preparation: July 2025
Approved by MHRA August 2025
© 2025 Novartis Pharmaceuticals UK Ltd. All rights reserved.

Patient name:

.....

**Patient ID
(for controlled access):**

.....

**Emergency contact name
and number:**

.....

.....

**Prescribing doctor name
and number:**

.....

.....